Xenetic Biosciences Inc XBIO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-11-07 |
| Shares Out. | 2,290,000 |
| Website | xeneticbio.com/ ↗ |
| Phone | 17817787720 |
| Employees | 2 |
| Revenue | $806,923 |
| Gross Profit | $806,923 |
| Net Income | -$456,382 |
| Total Assets | $7.9M |
| Total Liabilities | $958,239 |
| Equity | $7.0M |
About Xenetic Biosciences Inc
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Xenetic Biosciences Inc is a publicly traded company under the ticker symbol XBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-02-01)